# A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

> **NCT04921111** · PHASE1 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- HPV Infection Vaccine Safety SCT1000

## Interventions

- **DRUG:** SCT1000
- **DRUG:** Gardasil®9
- **DRUG:** placebo
- **DRUG:** Gardasil®

## Key facts

- **NCT ID:** NCT04921111
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-02
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04921111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04921111, "A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04921111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*